View Now | CP-RND: An Introduction to the Patient Community

Hosted by the C-Path team, you can view this recorded webinar to learn more about the Critical Path for Rare Neurodegenerative Diseases public-private partnership.

This webinar and patient-focused roundtable will deliver an enhanced understanding of:

• The CP-RND strategic plan, its stakeholder groups and program deliverables
• The envisioned impact of CP-RND on medical product development in rare neurodegenerative diseases
• Perspectives from patients, regulators and the industry on the public-private partnership and the rare neurodegenerative disease community

Speakers and panelists included:

Ronald J. Bartek Co-founder/President, Friedreich’s Ataxia Research Alliance	Lauren Boak, PhD Lifecycle Leader, GPS NSRD, Roche	Michelle Campbell, PhD Associate Director, Stakeholder Engagement and Clinical Outcomes, U.S. Food and Drug Administration
Jacqueline Corrigan-Curay, JD, MD Principal Deputy Center Director, Center for Drug Evaluation and Research, U.S. Food and Drug Administration	Philip Green ALS Patient Advocate	Collin Hovinga, PharmD, MS, FCCP Vice President of the Rare and Orphan Disease Programs, Critical Path Institute
Walter Koroshetz, MD Director, National Institute of Neurological Disorders and Stroke	Terina N. Martinez, PhD Executive Director, Critical Path for Rare Neurodegenerative Diseases, Critical Path Institute	Klaus Romero, MD, MS, FCCP Chief Science Officer; Executive Director of Clinical Pharmacology, Critical Path Institute
	Celia Witten, MD, PhD Deputy Director, Center for Biologics Evaluation and Research, U.S. Food and Drug Administration